Emicizumab Kxwh

Antihaemorrhagic/Antihemophilic · Coagulation Factor; Monoclonal Antibody

Indications

Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and paediatric patients ages newborn and older with haemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.

Dosage

INJECTION: SC: Recommended loading dose is 3 mg/kg once wkly for the first 4 wks, followed by a maintenance dose of: 1.5 mg/kg once every wk, or 3 mg/kg once every 2 wks, or 6 mg/kg once every 4 wks.

Administration

Administered subcutaneously. If prescribed dose is more than 2 mL, you will need to give more than one inj of emicizumab. Clean the chosen inj site area using an alcohol wipe. Let the skin dry for about 10 sec. You can use your thigh (front and middle) or stomach area (abdomen), except for 2 inches around the navel (belly button) or outer area of the upper arm (only if a caregiver is giving the inj). Use diff inj site each time. Preparation and Administration: Remove vial cap and clean top. Attach transfer needle to syringe. Uncap transfer needle. Inject air into vial. Transfer emicizumab to syringe. Remove air bubbles. Recap transfer needle. Clean inj site. Remove transfer needle. Attach inj needle to syringe. Move safety shield. Uncap inj needle. Adjust plunger to prescribed dose. Inject subcutaneously. Cover needle with safety shield. Dispose off the used vial, needle and syringe If…

Adverse Effects

Headache, diarrhoea, arthralgia, myalgia, pyrexia, inj site reactions.

Risk Factor (Pregnancy/Lactation)

Pregnancy: Contraindicated in pregnancy. Lactation: Contraindicated or not recommended. Precautions: Immune tolerance induction. Monitor for thrombotic microangiopathy (TMA) and thromboembolism when co-administering activated prothrombin complex concentrate (aPCC); discontinue aPCC and interrupt treatment if occur. Moderate to severe renal or hepatic impairment. Follow bypassing agent dosing guidance for =6 months after end of treatment. Risk factors for TMA. Surgery. Elderly >77 years.

Interactions

Drugs known to cause TMA (eg, cyclosporine, quinine, tacrolimus), bypassing agents (eg, aPCC), rFVIIa, FVIII.

Advice to Patient

Discontinue prophylactic use of bypassing agents the day before starting Emicizumab prophylaxis. Prophylactic use of FVIII may be continued for the first wk of Emicizumab prophylaxis. Inform prescriber if any signs or symptoms of thrombotic microangiopathy/thromboembolism occurs. These symptoms include: Confusion, weakness, swelling of arms/legs, yellowing of skin/eyes, stomach/back pain, nausea, vomiting, feeling sick, reduced urination, shortness of breath, chest pain/tightness, fast heart rate, coughing up blood, headache, eye pain/swelling, trouble seeing, face numbness. Follow the recommendations in the FDA-approved patient labeling regarding proper sharps disposal.

Pharmacokinetics

Bioavailability: Absolute: 1 mg/kg dose: 80.4%-93.1%. Half-life elimination: 26.9±9.1 days.

Compiled by Healify Pharmacy from published drug references. How we compile it →

Always consult a pharmacist or doctor.